Emerging strategies to overcome resistance to third-generation EGFR inhibitors

Table 3 Combination therapy with the bypass pathway target

Target	Representative compound*	Reference
MET	Cabozantinib	[145, 146]
MET	Crizotinib	[147]
MET	Savolitinib	[148]
FGFR	AZD4547	[149]
ALK	Lorlatinib	[150]
ALK	Brigatinib	[151]
HER2	JQ1	[152]
HER2	Trastuzumab-DM1	[153]
BRAF V600E	Encorafenib (LGX818)	[64]
AURK B	PF-03814735	[60, 154]

ISSN: 1756-8722